Abstract:
본 발명은 세포의 체외 배양 시 세포자멸사를 억제하기 위한 조성물에 관한 것으로서, 상세하게는 고농도의 칼륨을 포함하는 세포자멸사 억제용 배지 조성물, 상기 조성물 및 항산화제를 포함하는 배지 조성물, 상기 조성물과 항산화제 및 동결 보호제를 포함하는 배지 조성물, 및 상기 배지 조성물들을 이용하여 체외 배양 세포의 세포자멸사를 억제하는 방법에 관한 것이다.
Abstract:
본 발명은 양극성 장애 치료제의 스크리닝 방법에 관한 것으로서, 보다 구체적으로, 본 발명은 시료에 양극성 장애 치료제 후보 물질을 투여하고, 시료의 이온 채널의 활성을 측정한 다음, 상기 후보 물질이 TREK1 채널만을 활성화시키는 경우, 양극성 장애 치료제로 판정하는 단계를 포함하는 양극성 장애 치료제의 스크리닝 방법에 관한 것이다. 본 발명의 스크리닝 방법을 이용하면, 양극성 장애에 대한 치료효과를 나타낼 수 있는 물질을 용이하게 검출할 수 있으므로, 양극성 장애의 치료 또는 예방에 널리 활용될 수 있을 것이다.
Abstract:
PURPOSE: A pharmaceutical composition containing recombinant expression vector containing a gene encoding TASK-3 proteins is provided to effectively suppress cancer metastasis. CONSTITUTION: A pharmaceutical composition for suppressing cancer metastasis contains TASK-3 protein, a gene encoding the protein, or expression vector for gene therapy as an active ingredient and further contains pharmaceutically acceptable protein. The TASK-3 protein has an amino acid sequence of sequence number 21. The gene encoding TASK-3 contains a base sequence of sequence number 22. The recombinant expression vector contains the gene. A composition additionally contains an anticancer agent.
Abstract:
PURPOSE: A composition containing potassium of high concentration for suppressing apoptosis in cell culture in vitro is provided to regularly maintain cell area. CONSTITUTION: A medium composition for suppressing cell apoptosis contains 10-50 mM of potassium. The composition additionally contains antioxidant. The antioxidant is beta-mercaptoethanol or glutathione. The composition additionally contains cryopreservative, EFS solution. The cell is human in vitro culture cell or bovine in vitro culture cell.
Abstract:
PURPOSE: A method for screening a therapeutic agent for treating bipolar disorder is provided to easily detect a material which treats bipolar disorder and to prevent or treat bipolar disorder. CONSTITUTION: A method for screening a therapeutic agent for treating bipolar disorder comprises: a step of administering a candidate therapeutic agent to a sample; a step of detecting the activation of TREK1 and TREK2 channels in the sample; a step of determining the candidate therapeutic agent treats bipolar disorder when the only TREK1 channel is activated. The sample is a cell with TREK1 and TREK2 channels at the cell membrane. The cell is nerve cells.
Abstract:
PURPOSE: A pharmaceutical composition is provided to suppress NO generation in vivo or in a macrophage and to prevent or treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains an aged black garlic extract as an active ingredient. The extract is prepared by hot water extraction. The extract suppresses NO generation in a macrophage or in vivo. The composition additionally contains a pharmaceutically acceptable diluent, excipient, or carrier. A health functional food for preventing or treating inflammatory diseases contains the extract.
Abstract:
본 발명은 홍마늘 추출물을 포함하는 호흡기 세포 사멸에 의해 유도되는 질환의 예방 또는 치료용 조성물에 관한 것으로, 홍마늘 추출물이 호흡기 세포내 글루타티온의 농도 감소를 억제시키므로 상기 홍마늘 추출물을 포함하는 본 발명에 따른 조성물은 호흡기 세포 사멸에 의해 유도되는 질환의 예방 및 치료에 유용하게 사용될 수 있다.
Abstract:
PURPOSE: A composition containing red garlic extract is provided to suppress reduction of respiratory intracellular glutathione concentrations and to treat and prevent diseases caused by respiratory cell apoptosis. CONSTITUTION: A composition for preventing or treating diseases caused by respiratory cell apoptosis contains red garlic extract as an active ingredient. The apoptosis of respiratory cells is induced by cigarette smoke inhalation. The red garlic extract is isolated by hot water. A pharmaceutical composition for preventing or treating diseases caused by respiratory cell apoptosis contains the red garlic extract as an active ingredient. A composition for suppressing reduction of intracellular glutathione concentration in respiratory contains the red garlic extract as an active ingredient.